HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $80

Benzinga · 04/08 11:50
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $70 to $80.